Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
50
INSM Quote, Financials, Valuation and Earnings
Last price:
$70.58
Seasonality move
:
7.61%
Day range:
$68.80 - $71.07
52-week range:
$21.92 - $80.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.92x
P/B ratio:
26.07x
Volume:
5.7M
Avg. volume:
1.9M
1-year change:
154.2%
Market cap:
$12.6B
Revenue:
$305.2M
EPS (TTM):
-$5.55
Analysts' Opinion
-
Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Insmed has an estimated upside of 26.91% from its current price of $70.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $70.44.
Fair Value
-
According to the consensus of 0 analysts, Insmed has 26.91% upside to fair value with a price target of -- per share.
INSM vs. S&P 500
-
Over the past 5 trading days, Insmed has overperformed the S&P 500 by 0.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Insmed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Insmed has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Insmed reported revenues of $93.4M.
Earnings Growth
-
Insmed has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Insmed reported earnings per share of -$1.27.
Enterprise value:
12.1B
EV / Invested capital:
8.41x
Price / LTM sales:
31.92x
EV / EBIT:
--
EV / Revenue:
35.25x
PEG ratio (5yr expected):
-2.39x
EV / Free cash flow:
-19.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$264.9M
Return On Assets:
-56.29%
Net Income Margin (TTM):
-252.01%
Return On Equity:
--
Return On Invested Capital:
-85.94%
Operating Margin:
-212.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $242.2M | $280.8M | $343M | $79.1M | $93.4M | |
| Gross Profit | $186.8M | $220.6M | $264.9M | $62.4M | $72.3M | |
| Operating Income | -$424.9M | -$671.6M | -$703.9M | -$138.7M | -$198.7M | |
| EBITDA | -$405.9M | -$639.3M | -$769.6M | -$136.5M | -$196.5M | |
| Diluted EPS | -$3.64 | -$5.27 | -$5.55 | -$1.11 | -$1.27 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $667.1M | $959M | $632.2M | $926.6M | $1.6B | |
| Total Assets | $840.7M | $1.3B | $994.8M | $1.3B | $2.1B | |
| Current Liabilities | $83.9M | $112.5M | $137.7M | $196.7M | $259.2M | |
| Total Liabilities | $483.7M | $806.9M | $1B | $1.6B | $1.6B | |
| Total Equity | $357.1M | $504.8M | -$30M | -$289.4M | $483.4M | |
| Total Debt | $351.1M | $557.6M | $784.8M | $1.1B | $954.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$381.4M | -$508.6M | -$618.7M | -$136.3M | -$180.9M | |
| Cash From Investing | -$106.1M | -$205.1M | -$713.1M | $7.1M | -$1B | |
| Cash From Financing | $55.6M | $788.6M | $1.3B | $1.2M | $397.2M | |
| Free Cash Flow | -$387.8M | -$524.4M | -$636M | -$139.2M | -$184.6M | |
INSM
Sector
Market Cap
$12.6B
$43.9M
Price % of 52-Week High
87.47%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
154.2%
-29.11%
Beta (5-Year)
1.103
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$71.87
200-day SMA
Buy
Level
$58.56
Bollinger Bands (100)
Sell
Level
70.62 - 75.44
Chaikin Money Flow
Sell
Level
-33.6M
20-day SMA
Sell
Level
$73.26
Relative Strength Index (RSI14)
Sell
Level
44.65
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-82.5983
50-day SMA
Sell
Level
$72.29
MACD (12, 26)
Sell
Level
-0.39
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
130.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.7724)
Sell
CA Score
(Annual)
Level (-5.0814)
Buy
Beneish M-Score
(Annual)
Level (-2.8955)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.1536)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Stock Forecast FAQ
In the current month, INSM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INSM average analyst price target in the past 3 months is --.
-
Where Will Insmed Stock Be In 1 Year?
According to analysts, the consensus estimate is that Insmed share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Insmed?
Analysts are divided on their view about Insmed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Insmed is a Sell and believe this share price will drop from its current level to --.
-
What Is Insmed's Price Target?
The price target for Insmed over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INSM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Insmed is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INSM?
You can purchase shares of Insmed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Insmed shares.
-
What Is The Insmed Share Price Today?
Insmed was last trading at $70.58 per share. This represents the most recent stock quote for Insmed. Yesterday, Insmed closed at $70.44 per share.
-
How To Buy Insmed Stock Online?
In order to purchase Insmed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
